BioSpace News Archive

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), today announced that patient dosing was initiated in the anti-PD-1 refractory cutaneous squamous cell carcinoma (CSCC) arm of a Phase 2 multi-indication study evaluating the efficacy and safety of vidutolimod in combination with cemiplimab for the treatment of patients with anti-PD-1 refractory CSCC.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings.

Talaris Therapeutics, Inc. today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), active prior to market open today.

PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM),, and LTS LOHMANN Therapie-Systeme AG (“LTS”), today announced they have entered into a process development agreement for the clinical trial scale up of PharmaTher’s proprietary Ketamine microneedle patch product.

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors.

Viridian Therapeutics, Inc. today announced the first subject was dosed in a Phase 1/2 proof-of-concept clinical trial for VRDN-001.

Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200.

Benjamin Franklin Institute of Technology announced today a partnership with Ginkgo Bioworks (NYSE: DNA) to develop an associate degree in biotechnology manufacturing.

Senti Biosciences, Inc. and Dynamics Special Purpose Corp. today announced they have entered into a definitive business combination agreement to create a public company focused on Gene Circuit-engineered cell and gene therapies.